Drug Profile
N acetylcysteine amide - Nacuity Pharmaceuticals
Alternative Names: AT-001 - Arctic Therapeutics; NACA - Nacuity Pharmaceuticals; NPI-001Latest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Nacuity Pharmaceuticals
- Class Eye disorder therapies; Neuroprotectants; Small molecules; Sulfhydryl compounds
- Mechanism of Action Antioxidants; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cystinosis; Usher syndromes
- Phase I Retinitis pigmentosa
Most Recent Events
- 12 Mar 2024 European Medicines Agency (EMA) grants approval for clinical trial for N-acetylcysteine-amide in Familial cerebral amyloid angiopathy in Iceland
- 12 Mar 2024 Arctic Therapeutics plans a clinical trial in Familial cerebral amyloid angiopathy in Iceland
- 29 Oct 2023 Phase-I/II clinical trials in Cystinosis (In children, In adolescents, In adults, In the elderly) in Australia (PO) (NCT05994534)